Data Published in Prenatal Diagnosis Demonstrate Natera’s Non-Invasive Prenatal Testing Technology Enables Accurate Detection of Chromosomal Abnormalities Using Maternal Blood

SAN CARLOS, Calif.--(BUSINESS WIRE)--Natera today announced that data from a clinical study published in Prenatal Diagnosis demonstrate the ability of the company’s non-invasive prenatal screening test to detect chromosomal abnormalities from fetal cell-free DNA found in maternal blood with high accuracy.